ArticleERJ open research2025
Association of novel antihyperglycaemic drugs
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring health consequences of Asthma-COPD overlap syndrome in a national study.Scientific reports · 2026Article
- Cigarette Smoking-Induced Glucose Metabolic Reprogramming in Chronic Obstructive Pulmonary Disease: Mechanisms and Therapeutic Implications.International journal of chronic obstructive pulmonary disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dipeptidyl peptidase-4 inhibitors (DPP-4 Is), glucagon-like peptidase 1 receptor agonists (GLP-1 RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2 Is) may contribute to better control of COPD due to their anti-inflammatory effects, like those observed with metformin. We aimed to investigate the association of these novel antihyperglycaemic drugs Methods: Using the national administrative database covering 99% of the medical facilities in Japan, we constructed three active comparators new-user cohorts comprising 36 317 patients with T2DM and COPD who initiated treatment with the novel antihyperglycaemic drugs and metformin between 2014 and 2022. Patients' backgrounds were balanced using overlap propensity score weighting. We calculated the hazard ratios (HRs) and their 95% confidence intervals (CIs) for the initial occurrence of COPD exacerbation requiring systemic corticosteroids using a weighted Cox proportional hazards model. Results: DPP-4 Is were associated with a higher incidence of exacerbations requiring systemic corticosteroids (22.4 Conclusions: While DPP-4 Is were associated with poorer control of COPD compared with metformin, GLP-1 RAs and SGLT-2 Is offered COPD control comparable with that of metformin.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.